

Special Issue

From Biomarkers to Breakthroughs: Advancing Lung Cancer Research

Message from the Guest Editors

Lung cancer remains the leading cause of cancer-related mortality worldwide, with significant unmet clinical needs across diagnosis, prognosis, and treatment. Over the past few decades, substantial advances have been made in identifying molecular biomarkers, paving the way for more personalized and targeted therapeutic approaches. This Special Issue, entitled "From Biomarkers to Breakthroughs: Advancing Lung Cancer Research," aims to bring together cutting-edge research and clinical insights that span the continuum from biomarker discovery to translational applications. We invite contributions that explore novel diagnostic markers, predictive and prognostic tools, molecular targets, and resistance mechanisms in both non-small cell and small cell lung cancer. Original research articles, comprehensive reviews, and real-world data analyses are welcome, particularly those that highlight multidisciplinary strategies, integrate omics data, or examine patient-centered approaches to precision oncology. Our goal is to foster a deeper understanding of the molecular underpinnings of lung cancer and support the ongoing evolution of individualized patient care.

Guest Editors

Prof. Dr. Konstantinos Syrigos

Third Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, School of Medicine, 11527 Athens, Greece

Dr. Marousa Kouvela

Section of Medical Oncology, 3rd Department of Internal Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, Medical School, 52, Mesogeion Avenue, 11527 Athens, Greece

Deadline for manuscript submissions

15 March 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/2444501

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).